Search
for
Sort by
Research 151–180 of 279
- Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease
- PNU 157706, a novel dual type I and II5α-reductase inhibitor
- POSTĘP W DIAGNOZIE I LECZENIU STWARDNIENIA ROZSIANEGO
- PŁYNY- NIE ZA DUŻO, NIE ZA MAŁO, LECZ W SAM RAZ
- Chemotherapy‐induced alopecia management: Clinical experience and practical advice
- What do we know about phytotherapy of benign prostatic hyperplasia?
- Chemopr�vention des Prostatakarzinoms
- New ester derivatives of dehydroepiandrosterone as 5α-reductase inhibitors
- Lack of androgen receptor transcriptional activity in human keratinocytes
- Radiosensitization and Radioprotection by Curcumin in Glioblastoma and Other Cancers
- Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
- Dutasteride
- Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients
- Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
- Clinical Conditions Targeted by OnabotulinumtoxinA in Different Ways in Medicine
- Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review
- Hormonal manipulation of benign prostatic hyperplasia
- Do Anti-androgens Have Potential as Therapeutics for COVID-19?
- 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
- β‐Sitosterol—Dietary sources and role in cancer and diabetes management
- Protein Kinase C as a Therapeutic Target
- Chemistry, Pharmacology and Therapeutic Potential of Decursin: A Promising Natural Lead for New Drug Discovery and Development
- Alternative androgen pathways
- Life Sciences Discovery and Technology Highlights
- Minoxidil May be a Partial Agonist of Estrogen Receptor Alpha
- Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor
- Recent approaches of antibody therapeutics in androgenetic alopecia
- Therapeutic Potential of Brassinosteroids in Biomedical and Clinical Research
- GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
- Evolving CRBN ligands enhance the drug-like properties of protein degraders